How did Moleculin Biotech's Q1 2024 results compare to Q1 2023?

Moleculin Biotech's Q1 2024 results showed a significant improvement compared to Q1 2023. The company's net income loss for Q1 2024 was $4.97 million, while for Q1 2023, it was $7.92 million. This indicates a substantial reduction in the company's net loss, suggesting improved financial performance and operational efficiency.

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|MBRX|MBRX.O|Moleculin Biotech|2023 Q2|11.819389110225764|-5976000|186|
|MBRX|MBRX.O|Moleculin Biotech|2023 Q3|34.862385321100916|-5609000|186|
|MBRX|MBRX.O|Moleculin Biotech|2023 Q4|-51.68389955686854|-1.0269E7|186|
|MBRX|MBRX.O|Moleculin Biotech|2024 Q1|37.20783322804801|-4970000|186|

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|MBRX|MBRX.O|Moleculin Biotech|2022 Q2|-59.68426013195099|-6777000|186|
|MBRX|MBRX.O|Moleculin Biotech|2022 Q3|-96.64306919387988|-8611000|186|
|MBRX|MBRX.O|Moleculin Biotech|2022 Q4|-139.64601769911505|-6770000|186|
|MBRX|MBRX.O|Moleculin Biotech|2023 Q1|-15.26139507790884|-7915000|186|